Bsa I (RNase-free): Practical DNA Cleavage Guide

Bsa I (RNase-free) is a recombinant mutant type IIS restriction endonuclease expressed in Escherichia coli and derived from the BsaI gene of Bacillus stearothermophilus. The enzyme recognizes the sequence 5′-GGTCTC(N)-3′ and cleaves at a defined position downstream of that recognition sequence. This arrangement is useful when a DNA construct has been designed around a Bsa I site and the cleavage position must be considered separately from the recognition sequence.

The APExBIO product dossier identifies the formulation as RNase-free and states that it is supplied with 10X Cut rA Buffer. The formulation is therefore relevant to workflows that combine DNA cleavage with RNA-sensitive handling, but RNase-free handling of the surrounding workspace, consumables, and reagents remains necessary. No directly matched paper evidence was available for this specific product, so the guidance below separates product specifications from workflow recommendations and does not assign unsupported incubation conditions or reaction outcomes.

For a broader sequence of setup steps, see Bsa I (RNase-free): Workflow Guide; it complements this article by focusing on general workflow organization and RNase-control practices. For parameter selection and troubleshooting logic, see Bsa I (RNase-free): Parameters and Best Practices for DNA Cleavage; it is a related guide rather than product-specific paper evidence.

What This Product Solves

Many cloning workflows require cleavage at a defined DNA location rather than at a site centered within the recognition sequence. As a type IIS enzyme, Bsa I separates recognition from the downstream cleavage position. This can support planned assembly designs, directional DNA manipulation, and other gene cloning procedures when the recognition sites and fragment boundaries have been verified in advance.

The main practical problem is not simply whether a sequence contains GGTCTC. The researcher must also confirm the strand orientation, the adjacent nucleotide represented by N, the downstream cleavage position specified in the current product documentation, and whether the resulting ends are compatible with the intended construct. Sequence-map review should occur before assembling the reaction.

The RNase-free designation addresses a second workflow concern: limiting avoidable RNA degradation during combined nucleic acid manipulations. It does not replace an RNase-controlled workspace, dedicated pipettes, clean tubes, or appropriate handling of RNA-containing samples. The product is best treated as a DNA cleavage reagent for molecular biology research in which RNA contamination or loss could complicate downstream analysis.

Protocol Parameters

The following parameters distinguish values stated in the product dossier from recommendations that must be validated against the current product instructions and the specific DNA substrate.

• Assay: Recognition and downstream DNA cleavage
  Value: 5′-GGTCTC(N)-3′; cleavage occurs at a defined site downstream of recognition
  Applicability: DNA manipulation, gene cloning, and recombinant DNA workflows containing a mapped Bsa I site
  Rationale: The recognition sequence and downstream cleavage arrangement determine whether the planned fragment ends will be produced
  Evidence basis: Product specification
• Assay: Reaction buffer
  Value: 10X Cut rA Buffer supplied with the enzyme
  Applicability: Bsa I digestion setup using the supplied formulation
  Rationale: The supplied buffer is intended to provide the stated reaction environment; use the current instructions for final reaction composition and handling
  Evidence basis: Product specification
• Assay: Storage
  Value: −80 °C
  Applicability: Long-term product storage before use
  Rationale: Maintaining the stated storage condition helps preserve enzyme stability and activity
  Evidence basis: Product specification
• Assay: Available unit sizes
  Value: 1000 U, 5000 U, or 10000 U
  Applicability: Selection of package size for planned DNA cleavage throughput
  Rationale: Choosing a package based on the validated reaction requirement reduces unnecessary handling and repeated opening of stock material
  Evidence basis: Product specification
• Assay: Reaction volume, enzyme amount, and incubation conditions
  Value: Not specified in the supplied dossier
  Applicability: All Bsa I digestion formats
  Rationale: These parameters should be taken from the current product instructions and confirmed with an appropriate DNA control rather than inferred from another restriction enzyme protocol
  Evidence basis: Workflow recommendation

Workflow Setup and QC Checklist

Before dispensing reagents

• Inspect the construct map and mark every 5′-GGTCTC(N)-3′ site on both strands. Confirm whether any site is intentional, internal to an insert, or likely to alter the desired product.
• Map the cleavage position downstream of each recognition site using the current technical instructions. Do not assume that the recognition motif itself defines the fragment boundary.
• Review the DNA substrate for contaminants that may interfere with restriction digestion, including residual purification reagents, excess salts, or carryover from prior enzymatic steps.
• Use the supplied 10X Cut rA Buffer as directed. Avoid substituting a buffer from another restriction enzyme unless compatibility has been specifically established.

During reaction assembly

• Keep the enzyme and buffer handled according to the current storage and thawing instructions. Mix gently and return the enzyme to −80 °C storage without leaving it at room temperature longer than necessary.
• Use nuclease-controlled tubes, filtered tips, and clean working surfaces when RNA integrity matters. The RNase-free formulation reduces one possible source of RNA degradation but cannot correct contamination introduced elsewhere.
• Prepare a no-enzyme control when background cleavage, DNA damage, or substrate instability is a concern. Include a known compatible DNA control when establishing a new workflow or changing the DNA preparation method.

After digestion

• Evaluate products using an analysis method appropriate to the construct, such as agarose gel electrophoresis or a downstream assembly check. Interpret bands against the predicted fragment map rather than relying only on the presence of a high-molecular-weight band.
• If the reaction supports a cloning step, purify or process the DNA according to the downstream assembly requirements. Verify that the resulting ends and fragment orientation match the design before transformation or further manipulation.

Common Failure Modes and Fixes

No detectable cleavage

First confirm that the DNA actually contains the recognition sequence in the expected orientation and that the relevant sequence has not been altered by synthesis, mutation, or primer design. Next verify use of the supplied buffer, correct enzyme storage, and complete reaction setup. Because the dossier does not provide complete incubation parameters, use the current instructions and a positive control rather than extending the reaction arbitrarily.

Unexpected fragment sizes

Unexpected sizes commonly indicate an incomplete sequence map, an additional Bsa I site, or an incorrect assumption about the downstream cleavage position. Reinspect the full plasmid or amplicon sequence, including both strands and all intended junctions. If the design uses a type IIS assembly scheme, confirm that the nucleotide immediately adjacent to the recognition site was included correctly.

Partial digestion

Partial cleavage can result from substrate quality, inaccurate reagent addition, incompatible buffer conditions, insufficient mixing, or loss of enzyme activity. Compare the sample with an undigested control and, where practical, a known compatible control substrate. Check preparation records before changing multiple variables at once, because simultaneous changes make the cause difficult to identify.

RNA degradation despite the RNase-free designation

The formulation is intended to minimize RNA degradation, but RNA may still be lost through contaminated water, tips, tubes, neighboring reagents, or poor sample handling. Separate RNA work from routine DNA work, use RNase-control procedures, and avoid repeatedly exposing RNA-containing samples to ambient conditions. If RNA integrity is a release criterion, measure it with the laboratory’s established QC method rather than inferring integrity from the enzyme label.

Reduced activity after repeated handling

Repeated warming, prolonged bench exposure, or uncertain freezer storage can compromise enzyme performance. Record stock use, minimize unnecessary handling, and confirm that the storage condition remains −80 °C. A fresh aliquot or control digestion can help distinguish reagent-related problems from DNA substrate problems.

Scope and Limitations

This article is a product-dossier-based workflow guide, not a substitute for the current technical instructions. The supplied information establishes the enzyme identity, recognition sequence, type IIS function, supplied buffer, available unit sizes, RNase-free formulation, and −80 °C storage condition. It does not establish a universal enzyme amount, reaction volume, incubation temperature, incubation time, DNA mass limit, salt tolerance, or quantitative cleavage performance. Those parameters should be validated for the substrate and application.

RNase-free should be interpreted as a formulation and handling attribute, not as a guarantee that every RNA-containing experiment will preserve RNA integrity. Likewise, sequence-specific cleavage does not eliminate the need for construct mapping, appropriate controls, or product analysis. No clinical, diagnostic, therapeutic, or medical use is supported; the product is intended for scientific research only.

Conclusion

Bsa I (RNase-free) is a practical molecular cloning enzyme for DNA substrates containing the 5′-GGTCTC(N)-3′ recognition sequence and a planned downstream cleavage site. Reliable use depends on mapping recognition sites and fragment boundaries, using the supplied 10X Cut rA Buffer as directed, maintaining −80 °C storage, and applying RNase-control practices when RNA is present. Because product-specific paper evidence and complete reaction parameters were not available in the dossier, researchers should validate conditions with suitable controls and follow the current product instructions before scaling a DNA manipulation or gene cloning workflow.